產品詳情
簡單介紹：
Anti-Complement component C9a抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-Complement component C9a抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-Complement component C9a
Cat. Number:
Anti-Complement component C9a抗體KL-11190R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
C9 is a plasma protein synthesized in the liver and monocytes consisting of a single polypeptide chain. C9 is a part Anti-Complement component C9a抗體of the membrane attack complex (MAC), an important component of the immune system. The MAC forms upon complement system activation by invading pathogenic bacteria and consists of the four major complement proteins: C5b, C6, C7 and C8. These complement proteins bind to the outer surface of the plasma membrane of the invading cell. C9 binds to the membrane associated C5b-8 protein, which leads to the circular polymerization of 12-18 C9 molecules. These polymerized C9 molecules form a ring structure in the membrane. Molecules can then diffuse freely through this transmembrane channel, causing cell lysis and destruction of the invading bacterial cell.
Also known as:
C9a, C9 deficiency; Anti-Complement component C9a抗體C9a; C9 deficiency with dermatomyositis; CO9_HUMAN; Complement component 9; Complement component 9 deficiency; Complement component C9a; Complement component C9a; C9.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated synthetic peptide derived from human Complement component C9a.
●
Predicted Molecular Anti-Complement component C9a抗體Weight: 28/61kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-Complement component C9a抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
kl141Hu03 尿激酶型纖溶酶原激活因子受體(ukl)多克隆抗體 Polyclonal Antibody to Plasminogen Activator, Urokinase Receptor (ukl)
kl235Ra02 補體1抑制因子(C1INH)多克隆抗體 Polyclonal Antibody to Complement 1 Inhibitor (C1INH)
kl262Hu03 轉鐵蛋白受體2(TFR2)多克隆抗體 Polyclonal Antibody to Transferrin Receptor 2 (TFR2)
kl449Hu02 胱天蛋白酶7(CASP7)多克隆抗體 Polyclonal Antibody to Caskle 7 (CASP7)
kl537Hu02 神經元特異性烯醇化酶(NSE)多克隆抗體 Polyclonal Antibody to Enolase, Neuron Specific (NSE)
kl537Mu02 神經元特異性烯醇化酶(NSE)多克隆抗體 Polyclonal Antibody to Enolase, Neuron Specific (NSE)
kl547Mu02 血管細胞粘附分子1(VCAM1)多克隆抗體 Polyclonal Antibody to Vascular Cell Adhesion Molecule 1 (VCAM1)
kl556Ra02 角蛋白7(KRT7)多克隆抗體 Polyclonal Antibody to Keratin 7 (KRT7)
kl557Mu01 甲狀腺過氧化物酶(TPO)多克隆抗體 Polyclonal Antibody to Thyroid Peroxidase (TPO)
kl561Hu03 白血病抑制因子受體(LIFR)多克隆抗體 Polyclonal Antibody to Leukemia Inhibitory Factor Receptor (LIFR)
kl561Mu02 白血病抑制因子受體(LIFR)多克隆抗體 Polyclonal Antibody to Leukemia Inhibitory Factor Receptor (LIFR)
kl561Ra02 白血病抑制因子受體(LIFR)多克隆抗體 Polyclonal Antibody to Leukemia Inhibitory Factor Receptor (LIFR)
kl574Hu02 層粘連蛋白α1(LAMα1)多克隆抗體 Polyclonal Antibody to Laminin Alpha 1 (LAMa1)
kl601Mu02 髓過氧化物酶(MPO)多克隆抗體 Polyclonal Antibody to Myeloperoxidase (MPO)
kl615Mu03 纖溶抑制因子(TAFI)多克隆抗體 Polyclonal Antibody to Thrombin Activatable Fibrinolysis Inhibitor (TAFI)
kl626Ra02 胱天蛋白酶3(CASP3)多克隆抗體 Polyclonal Antibody to Caskle 3 (CASP3)
kl672Hu02 Slit同源物2(Slit2)多克隆抗體 Polyclonal Antibody to Slit Homolog 2 (Slit2)
kl692Mu02 神經纖維網蛋白1(NRP1)多克隆抗體 Polyclonal Antibody to Neuropilin 1 (NRP1)
kl692Mu03 神經纖維網蛋白1(NRP1)多克隆抗體 Polyclonal Antibody to Neuropilin 1 (NRP1)
kl692Mu04 神經纖維網蛋白1(NRP1)多克隆抗體 Polyclonal Antibody to Neuropilin 1 (NRP1)
kl711Hu02 肝素酶(HPA)多克隆抗體 Polyclonal Antibody to Heklanase (HPA)
kl775Mu02 己糖激酶1(HK1)多克隆抗體 Polyclonal Antibody to Hexokinase 1 (HK1)
